Hims & Hers Health is trading 9.87% down at €21.38 amid broader healthcare sector weakness and investor concerns regarding potential drug-price negotiations and policy shifts.
- The decline follows news of CVS Health’s planned restructuring, which has weighed on sentiment across the healthcare and pharmacy services space.
- No company-specific announcements were released to explain the move, though investors are looking ahead to the company's scheduled earnings report on November 9.